Literature DB >> 25091613

Liver cancer: time to evolve trial design after everolimus failure.

Josep M Llovet1.   

Abstract

Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. Now, the trial EVOLVE-1 has shown a lack of benefit for everolimus in the second-line treatment setting.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25091613     DOI： 10.1038/nrclinonc.2014.136

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

3.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 4.  Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Nat Rev Clin Oncol       Date:  2014-01-07       Impact factor: 66.675

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 6.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

7.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Authors:  Andrew X Zhu; Masatoshi Kudo; Eric Assenat; Stéphane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T P Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B Sellami; Li-Tzong Chen
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

Review 8.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

9.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  10 in total
  26 in total

Review 1.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

2.  Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Authors:  Adeola O Adebayo Michael; Sungjin Ko; Junyan Tao; Akshata Moghe; Hong Yang; Meng Xu; Jacquelyn O Russell; Tirthadipa Pradhan-Sundd; Silvia Liu; Sucha Singh; Minakshi Poddar; Jayvir S Monga; Pin Liu; Michael Oertel; Sarangarajan Ranganathan; Aatur Singhi; Sandra Rebouissou; Jessica Zucman-Rossi; Silvia Ribback; Diego Calvisi; Natalia Qvartskhava; Boris Görg; Dieter Häussinger; Xin Chen; Satdarshan P Monga
Journal:  Cell Metab       Date:  2019-01-31       Impact factor: 27.287

Review 3.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

4.  Targeting mTOR by CZ415 Suppresses Cell Proliferation and Promotes Apoptosis via Lipin-1 in Cervical Cancer In Vitro and In Vivo.

Authors:  Jinfeng Zhang
Journal:  Reprod Sci       Date:  2020-09-17       Impact factor: 3.060

5.  NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression.

Authors:  Sheng Tan; Hua Li; Weijie Zhang; Yunying Shao; Yuan Liu; Haiyang Guan; Jun Wu; Yani Kang; Junsong Zhao; Qing Yu; Yunzhao Gu; Keshuo Ding; Min Zhang; Wenchang Qian; Yong Zhu; Huayong Cai; Changyu Chen; Peter E Lobie; Xiaodong Zhao; Jielin Sun; Tao Zhu
Journal:  Oncogene       Date:  2018-05-21       Impact factor: 9.867

6.  Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription.

Authors:  Cecilia Patitucci; Gabrielle Couchy; Alessia Bagattin; Tatiana Cañeque; Aurélien de Reyniès; Jean-Yves Scoazec; Raphaël Rodriguez; Marco Pontoglio; Jessica Zucman-Rossi; Mario Pende; Ganna Panasyuk
Journal:  J Clin Invest       Date:  2017-04-10       Impact factor: 14.808

7.  Personalized management of hepatocellular carcinoma based on molecular information: future prospects.

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-06-01

8.  Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.

Authors:  Haojie Jin; Yurong Zhang; Haiyan You; Xuemei Tao; Cun Wang; Guangzhi Jin; Ning Wang; Haoyu Ruan; Dishui Gu; Xisong Huo; Wenming Cong; Wenxin Qin
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

9.  Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition.

Authors:  Tong-Hong Wang; Yong-Shiang Lin; Ying Chen; Chau-Ting Yeh; Yen-Lin Huang; Tsung-Han Hsieh; Tzong-Ming Shieh; Chuen Hsueh; Tse-Ching Chen
Journal:  Oncotarget       Date:  2015-09-15

Review 10.  Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.

Authors:  Massimiliano Berretta; Luca Rinaldi; Fabrizio Di Benedetto; Arben Lleshi; Vallì De Re; Gaetano Facchini; Paolo De Paoli; Raffaele Di Francia
Journal:  Front Pharmacol       Date:  2016-11-09       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.